United States

Report: INC Research to close clinical unit in W. Virginia

Thursday, April 26, 2012 03:01 PM

INC Research of Raleigh, N.C., confirmed it is closing its clinical study unit in Morgantown, W.V., according to an online report in The State Journal.

More... »

Targacept to reduce workforce, refocus company

Wednesday, April 25, 2012 02:47 PM

Targacept, a N.C.-based clinical-stage biopharmaceutical company developing novel NNR Therapeutics, plans to reduce its workforce by 65 employees, approximately 46%, as part of a strategic plan to focus the company's resources on its clinical programs and select preclinical opportunities.

More... »

Ipsen to relocate headquarters to New Jersey

Wednesday, April 25, 2012 10:59 AM

Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

More... »

Cetero reaches final resolution with FDA

Tuesday, April 24, 2012 03:10 PM

Cary, N.C.-based CRO Cetero Research has reached a final resolution with the FDA over studies the company conducted in its Houston bioanalytical laboratory between April 1, 2005 and June 15, 2010. Following months of open collaboration between Cetero and the agency, the FDA summarized its final decision:

More... »

Life Sciences venture capital investing falls in first quarter

Tuesday, April 24, 2012 12:21 PM

Venture capitalists invested $5.8 billion in 758 deals in the first quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. Quarterly venture capital (VC) investment activity fell 19% in terms of dollars and 15% in the number of deals compared to the fourth quarter of 2011, when $7.1 billion was invested in 889 deals.

More... »

Report: FDA strengthens monitoring of post-approval drug safety

Monday, April 23, 2012 10:19 AM

A strengthened and modernized post-market drug safety program has resulted in a substantial improvement in the FDA’s oversight of drugs once they reach the American public, according to a new report by the agency’s Center for Drug Evaluation and Research (CDER). The report, “Advances in FDA’s Safety Program for Marketed Drugs,” describes new scientific tools and enhanced capabilities that give the same priority to post-market drug safety monitoring as to premarket drug review.

More... »

Abbott touts positive results in phase III Parkinson's trial

Wednesday, April 18, 2012 03:39 PM

Abbott has released results from a phase III trial evaluating the company's investigational compound, levodopa-carbidopa intestinal gel (LCIG), for advanced Parkinson's disease.

More... »

Drug reduced number of MS lesions in phase II trial

Wednesday, April 18, 2012 12:37 PM

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase II clinical trial supported by Ono Pharmaceutical.

More... »

Eclipse wins exclusive worldwide antibody license from Dytax

Wednesday, April 18, 2012 09:58 AM

Burlington, Mass.-based biopharmaceutical company Dyax has granted Eclipse Therapeutics, a privately held oncology company of San Diego, exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax's gold-standard phage display technology for use in oncology indications.

More... »

MDI completes $1.9M Series B financing for Detect-Ready tests

Tuesday, April 17, 2012 07:30 AM

Molecular Detection Inc. (MDI), a Berwyn, Penn.-based company developing Detect-Ready tests designed to increase the speed and accuracy of infectious disease diagnosis, has completed a $1.9 million Series B recapitalization financing. 

More... »